Literature DB >> 16365726

Proteinuria and metabolic syndrome as predictors of cardiovascular death in non-diabetic and type 2 diabetic men and women.

A Juutilainen1, S Lehto, T Rönnemaa, K Pyörälä, M Laakso.   

Abstract

AIMS/HYPOTHESIS: Proteinuria predicts cardiovascular disease (CVD), but it is unclear whether this is explained by the association of the metabolic syndrome with proteinuria. Therefore, we investigated proteinuria and the metabolic syndrome as independent predictors of CVD death in men and women.
METHODS: The cohort comprised 574 non-diabetic men, 707 non-diabetic women, 371 diabetic men and 349 diabetic women, all free of CVD at baseline. Modified World Health Organization criteria were used to define the metabolic syndrome, and a urinary protein concentration of >or=0.1 g/l (or >or=0.2 g/l) to define proteinuria. The endpoint was CVD mortality during the 18-year follow-up.
RESULTS: Among non-diabetic men, CVD mortality per 1,000 person-years was as follows: no metabolic syndrome, no urinary protein group: 5.3; no metabolic syndrome, positive for urinary protein: 8.9; positive for metabolic syndrome, no urinary protein: 13.3; and positive for metabolic syndrome and urinary protein: 14.9. For non-diabetic women the corresponding values were: 0.9, 2.3, 4.9 and 7.9, respectively. Among diabetic men, CVD mortality per 1,000 person-years was 15.2, 32.5, 23.6 and 42.0 for the respective groups. Among diabetic women it was 25.3, 38.0, 26.3 and 40.3 (urinary protein in all cases defined as >or=0.1 g/l). In multivariate Cox models including both urinary protein and metabolic syndrome, the hazard ratios (HRs, 95% CI) of proteinuria for CVD mortality were 1.5 (0.9-2.4) in non-diabetic men, 1.8 (0.8-4.2) in non-diabetic women, 1.6 (1.0-2.6) in diabetic men and 1.6 (1.1-2.3) in diabetic women. Urinary protein as a continuous variable was associated with CVD mortality in all groups. The corresponding HRs for metabolic syndrome were: 1.6 (0.9-2.7), 4.0 (1.7-9.7), 1.5 (1.1-2.0) and 1.1 (0.8-1.5). CONCLUSIONS/
INTERPRETATION: Proteinuria predicted CVD mortality independently of the presence of metabolic syndrome in non-diabetic and diabetic subjects. Metabolic syndrome predicted CVD mortality in non-diabetic women and in diabetic men, independently of the presence of proteinuria.

Entities:  

Mesh:

Year:  2005        PMID: 16365726     DOI: 10.1007/s00125-005-0050-1

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  49 in total

1.  Microalbuminuria and associated cardiovascular risk factors in the community.

Authors:  P H Winocour; J O Harland; J P Millar; M F Laker; K G Alberti
Journal:  Atherosclerosis       Date:  1992-03       Impact factor: 5.162

2.  Relationship of elevated urinary albumin excretion to components of the metabolic syndrome in non-insulin-dependent diabetes mellitus.

Authors:  B Abuaisha; S Kumar; R Malik; A J Boulton
Journal:  Diabetes Res Clin Pract       Date:  1998-02       Impact factor: 5.602

3.  Microalbuminuria in hypertension is not a determinant of insulin resistance.

Authors:  Ingrid Toft; Kaare H Bønaa; Jorunn Eikrem; Ase Lund Bendiksen; Hege Iversen; Trond Jenssen
Journal:  Kidney Int       Date:  2002-04       Impact factor: 10.612

4.  Microalbuminuria: a major risk factor in non-insulin-dependent diabetes. A 10-year follow-up study of 503 patients.

Authors:  A Schmitz; M Vaeth
Journal:  Diabet Med       Date:  1988-03       Impact factor: 4.359

5.  Cardiovascular morbidity and mortality associated with the metabolic syndrome.

Authors:  B Isomaa; P Almgren; T Tuomi; B Forsén; K Lahti; M Nissén; M R Taskinen; L Groop
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

6.  Use of single voided urine samples to estimate quantitative proteinuria.

Authors:  J M Ginsberg; B S Chang; R A Matarese; S Garella
Journal:  N Engl J Med       Date:  1983-12-22       Impact factor: 91.245

7.  Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study.

Authors:  Graziella Bruno; Franco Merletti; Annibale Biggeri; Giuseppe Bargero; Stefania Ferrero; Cristina Runzo; Stefano Prina Cerai; Gianfranco Pagano; Paolo Cavallo-Perin
Journal:  Diabetes Care       Date:  2004-11       Impact factor: 19.112

8.  Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension.

Authors:  G Cerasola; S Cottone; G Mulé; E Nardi; M T Mangano; G Andronico; A Contorno; M Li Vecchi; P Galione; F Renda; G Piazza; V Volpe; A Lisi; L Ferrara; N Panepinto; R Riccobene
Journal:  J Hypertens       Date:  1996-07       Impact factor: 4.844

9.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

10.  Role of salt sensitivity, blood pressure, and hyperinsulinemia in determining high upper normal levels of urinary albumin excretion in a healthy adult population.

Authors:  Luigi X Cubeddu; Irene S Hoffmann; Lisette M Aponte; Rosaura Nuñez-Bogesits; Helimenia Medina-Suniaga; Magaly Roa; Robert S Garcia
Journal:  Am J Hypertens       Date:  2003-05       Impact factor: 2.689

View more
  6 in total

1.  The natural history of the non-nephrotic membranous nephropathy patient.

Authors:  Michelle A Hladunewich; Stephan Troyanov; Jennifer Calafati; Daniel C Cattran
Journal:  Clin J Am Soc Nephrol       Date:  2009-08-06       Impact factor: 8.237

2.  Prognostic value of International Diabetes Federation and Adult Treatment Panel III definitions of metabolic syndrome in Type 2 diabetic patients: what makes the difference?

Authors:  M Monami; N Marchionni; G Masotti; E Mannucci
Journal:  J Endocrinol Invest       Date:  2007-09       Impact factor: 4.256

3.  Metabolic syndrome and risk of mortality in middle-aged versus elderly individuals: the Nord-Trøndelag Health Study (HUNT).

Authors:  B Hildrum; A Mykletun; A A Dahl; K Midthjell
Journal:  Diabetologia       Date:  2009-02-05       Impact factor: 10.122

Review 4.  Circulating Cardiac Biomarkers in Diabetes Mellitus: A New Dawn for Risk Stratification-A Narrative Review.

Authors:  Alexander E Berezin; Alexander A Berezin
Journal:  Diabetes Ther       Date:  2020-05-19       Impact factor: 2.945

5.  Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women.

Authors:  Q Qiao
Journal:  Diabetologia       Date:  2006-10-05       Impact factor: 10.122

6.  Metabolic syndrome in children (Review).

Authors:  Yue-E Wu; Chong-Lin Zhang; Qing Zhen
Journal:  Exp Ther Med       Date:  2016-08-30       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.